

---

# Research update Biosergen: Continued success in India and cash injection

Carlsquare Equity Research has updated its view on Biosergen following the progress made in India and the report for the fourth quarter of 2024.

[Read the full update here.](#)

## About Carlsquare

---

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

## Contacts

---

### MARKUS AUGUSTSSON

Head of Equity Research

[markus.augustsson@carlsquare.com](mailto:markus.augustsson@carlsquare.com)

+46 (0)76 235 03 20

### NIKLAS ELMHAMMER

Senior Equity Analyst

[niklas.elmhammer@carlsquare.com](mailto:niklas.elmhammer@carlsquare.com)

+46 (0)70 898 39 59

## Attachments

---

[Research update Biosergen: Continued success in India and cash injection](#)